Playback speed
10 seconds
Targeted Therapy for High-Risk Myeloid Malignancies: Aza+/-Ven in Older AML Disease, Aza/Dec for MDS, Ven+Aza in Treatment-Naïve MDS, Ena/Ivo for IDH-Mutated MPN
84 views
February 15, 2021
Login to view comments.
Click here to Login